Patents by Inventor Samuel Moser

Samuel Moser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210083481
    Abstract: Method for regulating a bank of alternators comprising at least two alternators that deliver their output in parallel to a load (C), said alternators each being provided with a regulator (12, 13) that is configured to deliver an output signal representative of the reactive power level of the corresponding alternator divided by its nominal reactive power, and a control law allowing the reactive power level of the alternator to be modified depending on an input signal, method wherein a weighted signal employed as the input signal of these regulators is generated from the output signals representative of the reactive power level of each of the alternators, i.e. the signals delivered by the corresponding regulators, so as to make each of the alternators converge to a predefined reactive power level (Trp).
    Type: Application
    Filed: January 29, 2018
    Publication date: March 18, 2021
    Inventors: Vincent MORISSEAU, Jérémy FRATANI, Samuel MOSER, Jean-François PAILLOU
  • Publication number: 20210070873
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10851171
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 1, 2020
    Assignee: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20200291131
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: January 16, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Publication number: 20200283545
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 10, 2020
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20200255521
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? (further named also as “CD3”) and the extracellular domain of human ROR1 (further named also as “ROR1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° C. during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° C. and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or B-cell disorders expressing ROR1 and ROR1-positive solid tumors.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Tanja Fauti, Ramona Murr, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10683369
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 16, 2020
    Assignee: EngMab Sàrl
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20200106346
    Abstract: An electronic apparatus for a rotating electric machine, notably an alternator voltage regulator or speed variator, including an electronic circuit and a wired bus allowing the exchange of information with the outside, such that the bus is defined by an interface module rigidly fixed to a board of the electronic circuit and communicating via a wireless link with the latter.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 2, 2020
    Inventors: Emile Mouni, Christophe MONCHÃTRE, David Richard, Samuel Moser
  • Patent number: 10584178
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Publication number: 20200053907
    Abstract: An assembly comprising: an electronic device (1), in particular a variable speed drive or alternator regulator, comprising a casing, the rear of which is equipped with a heat sink (10), produced from a metal profile section, for cooling at least one power component; a first assembly of elements (20) for attaching the device on a support, each comprising at least one tab to be engaged in the profile section by sliding it therein, and an attachment lug provided with at least one screw through-hole; a second assembly of elements for attaching the device on a support, each comprising at least one tab to be engaged in the profile section by sliding it therein, and an attachment lug provided with at least one screw through-hole, the elements being of different shapes.
    Type: Application
    Filed: January 16, 2018
    Publication date: February 13, 2020
    Applicant: MOTEURS LEROY-SOMER
    Inventors: Samuel MOSER, Christophe GUITTON, Christophe MONCHATRE, Jean-Francois PAILLOU
  • Publication number: 20200053906
    Abstract: An electronic device, in particular a variable speed drive or alternator regulator, comprising a heat sink (10) and a power card comprising a printed circuit board, housed in a casing, characterized in that it comprises a part (100) attached, on the one hand, to the heat sink (10) and attached, on the other hand, to the board and coming into contact with at least one conductive track of the power card, so as to provide an electrical contact between the heat sink and said track, said part (100) having a face that is accessible from the outside of the device for attaching a lug connected to a ground and/or an earth cable.
    Type: Application
    Filed: January 16, 2018
    Publication date: February 13, 2020
    Applicant: MOTEURS LEROY-SOMER
    Inventors: Samuel MOSER, Christophe GUITTON, Sylvain GIRAUD, Jeremy FRATANI
  • Publication number: 20200052630
    Abstract: An electronic device, in particular an alternator regulator, comprising a power stage to be connected to an inductive load, in particular to an alternator inductor, comprising at least one first pair of power transistors connected to a terminal of a DC bus, and a control circuit for said transistors, the transistors being disposed in parallel between said terminal of the DC bus and a first output to be connected to the load, at least one flyback diode connecting the opposite terminal of the DC bus to the first output, the control circuit being designed to generate a pulsed control signal for regulating the current in the load and for detecting a failure of one of the transistors, the control circuit being designed, during normal operation, to send the control signal to one of the transistors of the first pair, while maintaining the other transistor of said pair in an off-state.
    Type: Application
    Filed: January 16, 2018
    Publication date: February 13, 2020
    Applicant: MOTEURS LEROY-SOMER
    Inventors: Samuel MOSER, Jeremy FRATANI, Vincent MORISSEAU, Jean-Francois PAILLOU
  • Publication number: 20190373762
    Abstract: An electronic device (1), in particular a variable speed drive or alternator regulator, comprising at least one power component mounted on a heat sink (10) and a plurality of capacitors extending through at least one opening of the heat sink, characterized in that it comprises a recess, which accommodates a sheet seal that is applied, on the one hand, on an internal face of the heat sink and, on the other hand, on an internal face facing a casing fitted onto the heat sink, with the internal faces of the heat sink and of the casing coming into contact.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Applicant: MOTEURS LEROY-SOMER
    Inventors: Samuel MOSER, Christophe GUITTON, Renaud LEBLANC, Vincent MORISSEAU
  • Publication number: 20190352427
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 21, 2019
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Duerner, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20190335604
    Abstract: An electronic device (1), in particular a variable speed drive or alternator regulator, comprising a casing, the front of which has a housing for accommodating an ancillary module, a hatch (150) for closing said housing, and an electronic circuit comprising an interface card defining a housing for accommodating a memory card, opening into the housing for accommodating the ancillary module
    Type: Application
    Filed: January 16, 2018
    Publication date: October 31, 2019
    Applicant: MOTEURS LEROY-SOMER
    Inventors: Samuel MOSER, Christophe GUITTON, David RICHARD, Jean-Francois PAILLOU
  • Publication number: 20190321557
    Abstract: A dosing device for an injection device, the dosing device including an actuating element for adjusting and/or dispensing a dose from the injection device, a thrust element for generating a forward movement for discharging a dose and a coupling to which the actuating element and the thrust element are coupled such that a rotational movement of the actuating element is transmitted directly to the thrust element and an axial movement of the actuating element is different than an axial movement of the thrust element.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Inventors: Stefan Burren, Jürg Hirschel, Samuel Martinoia, Ulrich Moser, Markus Tschirren
  • Patent number: 10350359
    Abstract: A dosing device for an injection device, the dosing device including an actuating element for adjusting and/or dispensing a dose from the injection device, a thrust element for generating a forward movement for discharging a dose and a coupling to which the actuating element and the thrust element are coupled such that a rotational movement of the actuating element is transmitted directly to the thrust element and an axial movement of the actuating element is different than an axial movement of the thrust element.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: July 16, 2019
    Assignee: TecPharma Licensing AG
    Inventors: Stefan Burren, Jürg Hirschel, Samuel Martinoia, Ulrich Moser, Markus Tschirren
  • Publication number: 20190211113
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moities capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Peter BRUENKER, Christina CLAUS, Claudia FERRARA KOLLER, Sandra GRAU-RICHARDS, Ralf HOSSE, Christian KLEIN, Viktor LEVITSKI, Samuel MOSER, Pablo UMANA
  • Patent number: 10253104
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: April 9, 2019
    Assignee: ENGMAB AG
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Publication number: 20180282410
    Abstract: The present invention generally relates to bispecific antigen binding molecules for activating T cells, more particularly bispecific antigen binding molecules for activating T cells targeting the Robo 4 receptor. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. In addition, the invention also relates to antibodies that specifically bind to Robo 4.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Oliver AST, Marina BACAC, Sabine BAUER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Samuel MOSER, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA, Tina WEINZIERL